Medpace (NASDAQ:MEDP) CEO Sells $274,978.62 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 458 shares of the company’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $600.39, for a total value of $274,978.62. Following the completion of the transaction, the chief executive officer owned 603,978 shares in the company, valued at $362,622,351.42. This represents a 0.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Medpace Price Performance

NASDAQ:MEDP opened at $578.50 on Monday. The stock has a market cap of $16.15 billion, a P/E ratio of 33.91, a PEG ratio of 2.58 and a beta of 1.15. The business’s 50-day moving average price is $536.23 and its two-hundred day moving average price is $491.58. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in Medpace in the second quarter worth $1,323,047,000. AQR Capital Management LLC grew its stake in shares of Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after buying an additional 404,226 shares during the last quarter. Madison Asset Management LLC purchased a new position in shares of Medpace in the second quarter worth about $128,956,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares during the period. Finally, American Capital Management Inc. bought a new stake in shares of Medpace in the 2nd quarter valued at about $111,329,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of research analyst reports. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and increased their price target for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Leerink Partners set a $620.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Truist Financial upped their target price on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Robert W. Baird increased their target price on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Finally, Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.